Charles Schwab Investment Management Inc Cytokinetics Inc Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,321,391 shares of CYTK stock, worth $64.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,321,391

Previous 925,682 42.75%

Holding current value

$64.6 Million

Previous $50.2 Million 39.11%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$51.22 - $60.16 $20.3 Million - $23.8 Million	395,709 Added 42.75%	1,321,391 $69.8 Million
Q2 2024 Aug 12, 2024	BUY	$47.86 - $75.05 $7.19 Million - $11.3 Million	150,126 Added 19.36%	925,682 $50.2 Million
Q1 2024 May 08, 2024	SELL	$63.75 - $108.06 $918,828 - $1.56 Million	-14,413 Reduced 1.82%	775,556 $54.4 Million
Q4 2023 Feb 06, 2024	BUY	$26.88 - $83.49 $893,948 - $2.78 Million	33,257 Added 4.39%	789,969 $66 Million
Q3 2023 Nov 08, 2023	SELL	$29.46 - $36.61 $423,222 - $525,939	-14,366 Reduced 1.86%	756,712 $22.3 Million
Q2 2023 Aug 09, 2023	BUY	$32.62 - $40.75 $1.58 Million - $1.97 Million	48,397 Added 6.7%	771,078 $25.2 Million
Q1 2023 May 11, 2023	SELL	$33.36 - $45.71 $113,457 - $155,459	-3,401 Reduced 0.47%	722,681 $25.4 Million
Q4 2022 Feb 13, 2023	BUY	$35.77 - $51.11 $746,519 - $1.07 Million	20,870 Added 2.96%	726,082 $33.3 Million
Q3 2022 Nov 14, 2022	BUY	$38.54 - $54.52 $3.79 Million - $5.35 Million	98,217 Added 16.18%	705,212 $34.2 Million
Q2 2022 Aug 15, 2022	BUY	$33.93 - $48.92 $220,646 - $318,126	6,503 Added 1.08%	606,995 $23.8 Million
Q1 2022 May 13, 2022	BUY	$29.74 - $46.0 $470,665 - $727,996	15,826 Added 2.71%	600,492 $22.1 Million
Q4 2021 Feb 11, 2022	SELL	$34.35 - $46.38 $922,881 - $1.25 Million	-26,867 Reduced 4.39%	584,666 $26.6 Million
Q3 2021 Nov 16, 2021	BUY	$18.54 - $35.74 $1.86 Million - $3.58 Million	100,229 Added 19.6%	611,533 $21.9 Million
Q2 2021 Aug 16, 2021	BUY	$19.79 - $26.99 $747,765 - $1.02 Million	37,785 Added 7.98%	511,304 $10.1 Million
Q1 2021 May 17, 2021	BUY	$18.57 - $25.68 $284,808 - $393,854	15,337 Added 3.35%	473,519 $11 Million
Q4 2020 Feb 16, 2021	BUY	$15.26 - $28.61 $142,391 - $266,959	9,331 Added 2.08%	458,182 $9.52 Million
Q3 2020 Nov 13, 2020	BUY	$20.58 - $28.96 $1.23 Million - $1.74 Million	59,962 Added 15.42%	448,851 $9.72 Million
Q2 2020 Aug 14, 2020	BUY	$11.15 - $24.64 $238,097 - $526,162	21,354 Added 5.81%	388,889 $9.17 Million
Q1 2020 May 15, 2020	BUY	$8.75 - $16.3 $78,863 - $146,911	9,013 Added 2.51%	367,535 $4.33 Million
Q4 2019 Feb 07, 2020	BUY	$7.95 - $11.84 $51,682 - $76,971	6,501 Added 1.85%	358,522 $3.8 Million
Q3 2019 Nov 08, 2019	BUY	$10.82 - $14.25 $240,160 - $316,293	22,196 Added 6.73%	352,021 $4.01 Million
Q2 2019 Aug 09, 2019	BUY	$7.95 - $11.25 $306,917 - $434,317	38,606 Added 13.26%	329,825 $3.71 Million
Q1 2019 May 14, 2019	BUY	$5.95 - $10.19 $38,460 - $65,868	6,464 Added 2.27%	291,219 $2.36 Million
Q4 2018 Feb 14, 2019	SELL	$5.91 - $9.29 $33,917 - $53,315	-5,739 Reduced 1.98%	284,755 $1.8 Million
Q3 2018 Nov 13, 2018	BUY	$6.4 - $9.85 $247,609 - $381,086	38,689 Added 15.36%	290,494 $2.86 Million
Q2 2018 Aug 08, 2018	BUY	$6.9 - $9.9 $178,109 - $255,548	25,813 Added 11.42%	251,805 $2.09 Million
Q1 2018 May 07, 2018	SELL	$7.2 - $10.05 $142,567 - $199,000	-19,801 Reduced 8.06%	225,992 $1.63 Million
Q4 2017 Jan 17, 2018	SELL	$7.25 - $15.65 $417,266 - $900,720	-57,554 Reduced 18.97%	245,793 $2 Million
Q3 2017 Nov 13, 2017	BUY	$12.0 - $15.0 $3.64 Million - $4.55 Million	303,347	303,347 $4.4 Million

Others Institutions Holding CYTK

# of Institutions

409

Shares Held

125M

Call Options Held

4.6M

Put Options Held

2.43M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.6B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Cytokinetics Inc Transaction History